antigens, the latter being the most frequent band observed in immunoglobulin M blots. Seroconversion was observed in 74 and 64% of evaluable patients by ELISA and IB, respectively, despite the use of antibiotic therapy.
Lyme disease, which is caused by Borrelia burgdorferi, is the most common vector-borne disease in the United States (6) . While the manifestations may be protean, diagnosis of early disease is frequently based on the presence of an expanding erythematous lesion, erythema migrans (EM). Although several laboratory tests can be used to assist in the diagnosis of early Lyme borreliosis, none has been completely satisfactory. The most direct approach is to attempt to culture the causative agent. Although cultures of skin biopsy samples from sites of EM may grow B. burgdorferi in up to 85% of cases (4, 29) , this technique is slow, laborintensive, and impractical for use in the clinical laboratory (24, 33) . Other direct diagnostic methods such as tests for the presence of antigen or the use of the polymerase chain reaction to detect B. burgdorferi nucleic acid sequences are also currently limited to use at the investigational level (2, 21, 22) . Consequently, laboratory methods that can be used to assist in clinical diagnosis have rested principally on indirect methods for detection of specific anti-B. burgdorferi antibodies. The enzyme-linked immunosorbent assay (ELISA) is the most widely used of these serological assays, but it may give both false-negative and false-positive results (9, 11, 20) .
Although not yet standardized for use in the diagnosis of Lyme borreliosis, the Western immunoblot assay (IB) should permit a clearer picture of which B.
burgdorfieri antigens elicit specific antibodies and define the temporal sequence in which antibodies appear. Reported results of IB testing of samples from patients with early disease have, however, involved only a limited number of patient sera (8, 10, 15, 19, 23, 36) . Recently, Dressler et al. (12) proposed revised criteria for the interpretation of IB results on the basis of a retrospective analysis of sera from patients with different stages of Lyme disease and applied * Corresponding author. these criteria to the interpretation of IB of serum specimens from 57 patients with EM.
We describe the results of ELISA and IB analyses of sera from 100 patients presenting with EM Diagnostic Center. Additional serum samples were obtained from 59 of these patients at approximately 1 month after the initial visit. For IB analysis, a control group of 69 serum samples was collected from individuals with systemic lupus erythematosus (n = 18), rheumatoid arthritis (n = 18), and syphilis (n = 10) (all 10 samples from patients with syphilis tested positive by both reagin and treponemal antibody tests) and from a group of healthy donors (n = 23); 10 of these healthy individuals were from an area in which Lyme disease is not endemic. Samples were stored at 5°C for up to 1 week. Long-term storage was at -70°C.
ELISA. All serum samples were assayed for their seroreactivities in Lyme Stat (Whittaker Bioproducts, Inc., Walk- A comparison of ELISA versus IB positivity in acutephase samples showed that, overall, IB was more sensitive than ELISA in detecting B. burgdorferi antibodies (43 versus 35%), but this difference was not statistically significant (P = 0.310) ( Table 2 ). On the basis of the duration of EM, the difference in sensitivity was greatest for patients with EM of <7 days' duration; sera from 14 of 55 (25%) and 7 of 55 (13%) of patients in this group were positive by IB and ELISA, respectively (P = 0.144). Of the seven serum samples in this group positive by IB but with discordant ELISA results, 4 were equivocal and 3 were negative by ELISA. Of the sera from the group of patients with EM of 7 to 14 days' duration, 2 serum specimens that were equivocal by ELISA and one serum specimen that was negative by ELISA were interpreted as positive by IB; one serum specimen that was positive by ELISA was interpreted as indeterminate by IB. Sera from 12 of 13 patients with EM of >14 days' duration who had a positive ELISA result also tested positive by IB.
The band reactivities observed in IB of acute-phase serum samples according to the duration of EM are shown in Fig. 1 . Overall, the 25-kDa band was the most frequently found The IB reactivities of sera from a control group in comparison with those of sera from patients with EM are shown in Table 3 . When present in control sera, IgM reactivity was directed against single antigens. For example, IgM reactivity was observed in sera from one patient with rheumatoid arthritis (39 kDa), one patient with systemic lupus erythematosus (31 kDa), and two patients with syphilis (weak reactivity to the 25-kDa antigen). More immunoreactive antigens were observed in the IgG blots, with the 41-and 60-kDa antigens being the most frequent, but none was interpreted as positive. Eight of 10 (80%) serum specimens from patients with syphilis had IgG-reactive blots, with an average of 1.7 bands. Thirty-nine percent of serum specimens from patients with systemic lupus erythematosus and 56% of serum specimens from patients with rheumatoid arthritis had IgG-reactive blots, with an average of 1.2 and 1.3 bands, respectively. Ten of 23 (43%) serum specimens from healthy donors had IgG-reactive blots, with an average of 1.5 bands.
Seroconversion. Twenty-three of 31 (74%) patients with EM whose sera were initially seronegative by ELISA seroconverted in the convalescent phase; sera from 7 (23%) patients became equivocal and sera from 16 (51%) patients became positive (Table 4 ). Seroconversion to positivity was observed in five of the seven patients (71%) whose sera had an equivocal ELISA result in the acute phase of disease. (3, 32) .
Although the overall percentage of ELISA reactivity appeared to be similar to those published in other reports, the probability of seroreactivity directly correlated with the duration of EM; 31% of sera were reactive by ELISA when the skin lesion was of less than 7 days' duration compared with 58 and 100% reactive sera by ELISA when EM was present for 7 to 14 days and greater than 14 days, respectively (P < 0.05 for each pairwise comparison). Whether seropositivity is as frequent in patients without EM but with Lyme borreliosis of the same duration is unknown.
Similar to ELISA, IB reactivity was found to be directly related to the duration of EM. The number of bands increased from an average of 1.6 and 2.0 for IgG-and IgMreactive blots, respectively, when patients sought medical attention within 7 days of the appearance of EM lesions to 5.6 and 4.6 for IgG-and IgM-reactive blots, respectively, for those patients with EM of greater than 14 days' duration (P < 0.05). Overall, sera from 65 patients had band reactivities by IB, 43 (66%) of which were considered positive by the criteria used in the interpretation of the results. Although sera from the majority of patients had both IgG and IgM reactivities (62%), isolated IgM reactivity was found in up to 36% of sera from patients with EM of short duration. Furthermore, 41 of the 43 (95%) positive blots met the IgM criteria for positivity. The two patients with positive blots based solely on IgG reactivity criteria had had EM in previous years. It is possible that in these two patients the antibodies detected were induced by prior infection with B.
burgdorferi; nonetheless, the possibility of a booster effect of the current infection cannot be excluded.
It has frequently been stated that early antibiotic therapy may prevent the development of specific antibodies (30, 34) . We found this to be less common than anticipated since 28 of 38 (74%) of our evaluable patients whose sera were initially seronegative or equivocal by ELISA and 21 of 33 (64%) patients whose sera were initially negative or indeterminate as determined by IB seroconverted with a single serum sample obtained approximately 1 month after the first visit.
Seroconversion was not affected by the choice of antibiotic therapy (data not shown). For the eight patients who did not seroconvert, as determined by ELISA, it could be postulated that the clinical diagnosis of EM was incorrect. However, in two of these patients, B. burgdorferi was isolated from the skin lesion, and one of these two patients seroconverted, as determined by IB. Of the remaining five patients, skin cultures were not available for three and were nonevaluable for the other two patients (because of overgrowth by other bacteria). All of these five patients had EM lesions of 2 to 7 days' duration.
Feder et al. (13) recently reported that antibodies in the sera of patients with EM may persist for as long as 3 years following therapy. Although sera from our patients were only tested at 1 month after the initial visit, we also noted the absence of reversion to negativity in the convalescent-phase serum samples from patients who were initially seropositive by ELISA or IB. The general pattern observed was an expansion of the IB band reactivity in convalescent-phase serum samples. However, sera from 6 of 26 (23%) patients positive by IB in the acute phase had decreased blot reactivity in the convalescent phase and were classified as indeterminate, and serum from one patient indeterminate by IB in the acute phase became negative in the convalescent phase. Of interest, the majority (97%) of the positive blots in the convalescent phase still met the IgM reactivity criteria for positivity, whereas only 25% fulfilled the IgG reactivity criteria. If convalescent-phase sera had been collected later than 1 month into the convalescence, the disparity in favor of IgM would likely have been less or reversed in favor of IgG positivity.
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As described by others (15, 16) , IB is more sensitive than ELISA for the detection of specific B. burgdorferi antibodies. This difference, although not statistically significant, was greatest in those patients with EM of less than 7 days' duration at the initial visit. Of interest, sera from all patients in this group that were positive by IB but negative by ELISA had an ELISA LIV greater than or equal to 0.6 (the threshold for the equivocal range was an ELISA LIV of 20.8). In addition, sera from five of the six patients with isolated IgM reactivity to the 25-kDa antigen band had a negative ELISA result; 2 of these serum specimens also had an ELISA LIV of >0.6. It is possible that the difference in sensitivities of the two methodologies in the present study is due to the use of a polyvalent ELISA rather than an IgM ELISA, which is our standard practice to screen for antibodies to B. burgdorferi. It 25 -kDa antigen have been described by others among U.S. patients with early Lyme disease, but at a frequency lower than that reported here (15, 19) . It seems likely that this is due to a difference in the antigen preparation used in the IB, since it has been shown that several antigens of B. burgdorfen, including a 25-kDa antigen, are expressed in variable amounts, depending on the in vitro conditions of growth of the organism (27, 28) . Furthermore, several B. burgdorferi proteins are known to be lost or underexpressed in strains that have undergone high numbers of passages (25) . Interestingly, in previous years, reactivity to the 25-kDa antigen was not observed in a similar patient population when immunoblots from the same manufacturer were used. It was only when the manufacturer began to use a low-passage B31 strain that this reactivity became evident. In their recent study, Dressler et al. (12) found that reactivity to a 21-kDa antigen was the most frequently present band in IgM IBs of sera from a group of patients with EM. In that report, B. burgdorferi G39/40 was used to prepare the blots, and it was demonstrated that this 21-kDa antigen also reacted with a monoclonal antibody to pC (L321F8) of B. Wilske. The discrepancies in the molecular sizes of these apparently similar or identical immunoreactive proteins can most likely be attributed to the different antigen preparations used or to technical differences in the preparation of the blots. Similar discrepancies in molecular size are likely to exist for other antigens. Since Dressler et al. (12) are proposing the use of specific antigens as significant immunoreactive bands, it is imperative that a consensus on nomenclature be established.
Aside from the results of Dressler et al. (12) , most investigators to date who use IB on sera from patients with early Lyme disease have found that the first detectable antibodies are directed to the 41-kDa protein corresponding to the flagellar antigen (8, 10, 15, 19, 23, 36) . We also found reactivity to this protein to be common but less frequent than reactivity to the 25-kDa protein in IgM blots of acute-phase sera. The high frequency of reactivity to the 41-kDa protein in IgG blots may be partially explained by the background prevalence of these antibodies in sera from patients without Lyme disease (12, 15, 19) , as was observed in the sera of our control group of patients. Antibodies against the 39-kDa antigen were observed in 26% of the IgG-reactive blots and 35% of the IgM-reactive blots during the acute phase of disease and were more commonly found in patients with EM of greater than 14 days' duration (50%). This parallels the findings of Ma et al. (19) , who reported IgM reactivity to the 39-kDa antigen in one-half of patients with early Lyme disease.
Since the earliest immunological response to infection with B. burgdorferi appears to be directed to the 25-and 41-kDa antigens, it may be important to include or perhaps enrich serological assays with these antigens for detection of antibodies in the early stage of disease. In our study, we found that in patients with EM of short duration, IgM reactivity to the 25-kDa antigen appears to be detectable the earliest. If we would have included this reactivity as specific for B. burgdorfeni infection, six additional patients in the acute phase of disease would have been interpreted as having a positive IB result.
Until a consensus is established for the interpretation of IB results for B. burgdorferi antibodies, we suggest that a distinct IgM reactivity to the 25-kDa antigen be considered strongly indicative of an early, specific antibody response to B. burgdorfen infection.
